Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Danielle McGeeney"'
Autor:
Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Kaifeng Lu, Kristi Womack, Danielle McGeeney, Antonia Periclou
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist approved by the US Food and Drug Administration for acute treatment of migraine with or without aura in adults. Objectives: To assess potential pharmacokine
Externí odkaz:
https://doaj.org/article/aa2b7c48d11545d49f7a5cd727513526
Publikováno v:
Clinical Pharmacology in Drug Development.
Autor:
Matthew Butler, Danielle McGeeney, Antonia Periclou, Li Yao, Brian McNamee, Lisa Borbridge, Ramesh Boinpally
Publikováno v:
Clinical Pharmacology in Drug Development
Atogepant is a selective, oral calcitonin gene–related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double‐blind, phase 1 crossover study evaluated the cardiac repolarization effect of a single
Autor:
Andrew M. Blumenfeld, Lisa Borbridge, Janette Contreras-De Lama, Abhijeet Jakate, Ramesh Boinpally, Antonia Periclou, Matthew Butler, Richard B. Lipton, Danielle McGeeney
Publikováno v:
Headache
Objective To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on the pharmacokinetic (PK) profile, safety, and tolerability of ubrogepant. Background People taking
Publikováno v:
Clinical pharmacology in drug development. 11(11)
Eluxadoline is a mixed μ-opioid, κ-opioid receptor agonist, and δ-opioid receptor antagonist, approved in the United States for adults with diarrhea-predominant irritable bowel syndrome. This phase 1, single-center, open-label, single-sequence stu
Autor:
Kaifeng Lu, Matthew Butler, Abhijeet Jakate, Danielle McGeeney, Ramesh Boinpally, Antonia Periclou
Publikováno v:
Headache
Objective To evaluate the potential for pharmacokinetic interaction and the safety and tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in healthy participants, and to inform the safety and tolerability of ubrogepant
Autor:
Danielle McGeeney, Antonia Periclou, Matthew Butler, Abhijeet Jakate, Ramesh Boinpally, Kaifeng Lu
Publikováno v:
Clinical Pharmacology and Therapeutics
Ubrogepant is a novel, oral calcitonin gene-related peptide receptor antagonist currently under US Food and Drug Administration (FDA) review for the acute treatment of migraine attacks. This double-blind, four-period crossover study compared the card